OS Therapies (NYSE:OSTX) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of OS Therapies (NYSE:OSTX) in a report published on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $20.00 price objective on the stock.

OS Therapies Stock Down 0.5%

Shares of OSTX stock opened at $1.99 on Tuesday. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $7.00. The stock has a market cap of $62.97 million and a P/E ratio of -2.52. The business has a fifty day simple moving average of $2.08 and a 200-day simple moving average of $1.82.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OSTX. CM Management LLC increased its position in shares of OS Therapies by 172.6% in the first quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $462,000 after buying an additional 189,956 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of OS Therapies during the second quarter valued at $63,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of OS Therapies during the second quarter valued at $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.